Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Biosciences' Q3 Revenues Climb 19 Percent

NEW YORK (GenomeWeb News) – Pressure Biosciences today reported that its third-quarter 2009 revenues increased 19 percent on higher grant revenue and a growing number of installations of its Barocycler instruments.

The South Easton, Mass.-based firm brought in total revenues of $317,427 for the three-month period ended Sept. 30, compared to $265,662 for the third quarter of 2008. Revenues from its pressure cycling technology products and services were $204,584 versus $222,825 in the comparable quarter of 2008, while its grant revenue increased to $112,843 from $42,837.

Pressure Biosciences said that it installed 20 of its Barocycler instruments during the quarter, compared to seventeen in the third quarter of 2008.

Its net loss for the quarter declined to $775,449, or $.35 per share, from $1.1 million, or $.50 per share.

The firm cut its spending year over year, with R&D expenses down 27 percent at $273,286 versus $376,552 the year before. Its SG&A expenses fell around 16 percent to $724,228 from $866,263.

Pressure Biosciences finished the quarter with $1.4 million in cash and cash equivalents.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more